14 unknown, 12 recruiting, 5 completed, 3 not yet recruiting. 13 Phase 2, 7 Phase 1, 4 Phase 4, 3 Not applicable, 2 Phase 3.
Follow Antineoplastic Agents: new trials by email Literature Review of Antineoplastic Agents trials Research Report on Antineoplastic Agents
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study to Evaluate the Efficacy and Safety of RAG-01 as Monotherapy and in Combination With Chemotherapy in Patients With Non-muscle Invasive Bladder Cancer (NMIBC). RAG-01, Chemotherapy agent - Non-muscle Invasive Bladder Cancer (NMIBC) | Phase 2 | Not yet recruiting | Ractigen Therapeutics. | 114 | 2026-09-01 | 2026-09-15 |
| Risk Prediction Scores for Cardiotoxicity in Cancer Patients Treated With Cardiotoxic Anticancer Therapies in Europe antineoplastic agents, endocrine therapy, immunostimulants drugs (ATC classification) - Cancer, Anticancer Treatment | Not yet recruiting | University Hospital, Caen | 10000 | 2026-06-22 | 2026-07-22 | |
| Short-Course Radiotherapy Followed by Immunotherapy Combined With Chemotherapy for Microsatellite Stable Locally Advanced Rectal Cancer: A Prospective, Randomized, Controlled Phase II Clinical Trial Sintilimab, Chemotherapy Drugs, radiotherapy - Rectal Cancer | Phase 2 | Recruiting | Tianjin Medical University Cancer Institute and Hospital | 130 | 2026-05-01 | 2026-05-19 |
| Perioperative Chemotherapy With Low-Dose Radiotherapy and Tislelizumab for Locally Advanced Gastric or Gastroesophageal Junction Adenocarcinoma Low Dose Radiotherapy Combined with Tislelizumab and Chemotherapy, Chemotherapeutic Agent, low-dose radiotherapy - Gastric or Gastroesophageal Junction Adenocarcinoma | Phase 2 | Not yet recruiting | Jiangsu Cancer Institute & Hospital | 114 | 2026-02-26 | 2026-02-13 |
| Efficacy of Neoadjuvant Immunotherapy in Patients With Lung Cancer Pneumonectomy, lobectomy, radiotherapy - Lung Cancer, Non-Small Cell, Immunotherapy | Recruiting | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 500 | 2025-04-20 | 2025-09-10 | |
| A First-in-Human Open-label, Phase I/Ib Dose Escalation and Expansion Cohort Study of EOS006215 as Monotherapy and in Combination With Pembrolizumab or Other Anticancer Treatments in Participants With Advanced Solid Tumors EOS006215, Anticancer agent - Selected Advanced Solid Tumors | Phase 1 | Terminated | iTeos Belgium SA | 3 | 2025-04-07 | 2025-08-12 |
| China Liver Cancer Clinical Registry Cohort Database (HEAL) Procedure/Surgery treatment, Anti-Tumor Drugs - Liver Cancer | Recruiting | Anhui Provincial Hospital | 10000 | 2025-01-01 | 2025-08-20 | |
| A First-in-Human (FIH) Study of BG-C137, an Anti-Fibroblast Growth Factor Receptor 2b (FGFR2b) Antibody Drug Conjugate, in Participants With Advanced Solid Tumors BG-C137, Anticancer Agents - Advanced Solid Tumor | Phase 1 | Recruiting | BeOne Medicines | 168 | 2024-12-09 | 2026-07-09 |
| The Effect of Serum Ferritin in irAE PD-1 and PD-L1 inhibitor, Targeted drugs, chemotherapy drugs - Immune-related Adverse Event, Malignant Solid Tumors | Not applicable | Recruiting | Tianjin Medical University Cancer Institute and Hospital | 1500 | 2024-07-04 | 2024-11-25 |
| Pharmacovigilance Assessment of Reporting of Cardiovascular Adverse Events With Antineoplastic Agents (PARCA) Antineoplastic Agents - Cardiovascular Diseases, Cardiac Diseases | Unknown | The First Affiliated Hospital of Xinxiang Medical College | 800000 | 2024-06-01 | 2024-05-10 | |
| The Study of Huaier Granule in Postoperative Adjuvant Therapy of Resectable Pancreatic Cancer Huaier granule, chemotherapy drugs - Pancreatic Cancer Resectable | Phase 4 | Recruiting | Xi'an Jiaotong University | 642 | 2024-05-06 | 2024-05-08 |
| Preoperative Neoadjuvant Immunotherapy Combined With Chemotherapy for Stage Ⅲ Unresectable Non-small Cell Lung Cancer Tislelizumab, Pemetrexed (Non-squamous NSCLC) or Nab-paclitaxel(Squamous NSCLC), Carboplatin or Cisplatin - Non-small-cell Lung Cancer (NSCLC) | Phase 4 | Unknown | The Affiliated Hospital of Qingdao University | 30 | 2024-01-18 | 2024-04-10 |
| DAY101 vs. Standard of Care Chemotherapy in Pediatric Participants With Low-Grade Glioma Requiring First-Line Systemic Therapy (LOGGIC/FIREFLY-2) Tovorafenib, Chemotherapeutic Agent - Low-grade Glioma, Rapidly Accelerated Fibrosarcoma (RAF) Altered Glioma | Phase 3 | Active not recruiting | Day One Biopharmaceuticals, Inc. | 418 | 2023-02-27 | 2026-10-19 |
| Pamiparib (BGB-290) Was Used in EGFR-TkIs Resistant Non-small Cell Lung Cancer Parimparib, Chemotherapy drug, Targeted Therapy Agent - Carcinoma, Non-Small-Cell Lung, EGF-R Positive Non-Small Cell Lung Cancer | Phase 1 | Unknown | Affiliated Hospital of Jiangnan University | 40 | 2022-12-20 | 2024-01-31 |
| ctDNA as a Biomarker for Treatment in Advanced NSCLC Immunotherapy, Chemotherapeutic Agent, Chemotherapy - Non-small Cell Lung Cancer | Unknown | Fuzhou General Hospital | 500 | 2022-07-31 | 2022-08-04 | |
| Correlation Between Myocardial Injury and Intestinal Flora Changes Associated With Oncology Drug Therapy Antitumor drugs - Cancer Therapy-related Cardiovascular Toxicity | Unknown | Peking University Third Hospital | 50 | 2022-07-01 | 2023-03-03 | |
| Evaluation of Reporting of Antibody-Drug Conjugate Associated Sepsis-related Toxicities Antibody-Drug Conjugate, Antineoplastic and immunomodulating agents other than Antibody-Drug Conjugate - Sepsis (SMQ), Opportunistic Infections | Completed | Central South University | 24618 | 2022-04-22 | 2022-06-22 | |
| Neoadjuvant Immunotherapy and Chemotherapy Followed by Surgery in Unresectable Stage Ⅲ NSCLC Carrelizumab, Pemetrexed (Nonsquamous NSCLC) or Nab-paclitaxel(Squamous NSCLC), Carboplatin - Non Small Cell Lung Cancer | Phase 2 | Unknown | Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | 30 | 2021-08-20 | 2021-09-02 |
| Evaluation of Reporting of AdVerse Events Associated With AnTicAncer theRapy (AVATAR) Antineoplastic and Immunomodulating Agents - Cancer | Unknown | University Hospital, Caen | 5000000 | 2021-01-01 | 2021-01-06 | |
| Fruquintinib in Refractory Metastatic Colorectal Cancer: A Real-world Study Fruquintinib - Colorectal Cancer, Refractory Colorectal Cancer | Completed | Fudan University | 520 | 2021-01-01 | 2024-01-11 |
Showing 20 of 39. Sign in to see all of them.
Neoplasms (7) · Carcinoma, Non-Small-Cell Lung (6) · Heart Diseases (3) · Breast Neoplasms (2) · Cardiotoxicity (2) · Cardiovascular Diseases (2) · Leukemia, Myeloid, Acute (2) · Small Cell Lung Carcinoma (2) · Vascular Diseases (2) · Agranulocytosis (1) · Carcinoma, Hepatocellular (1) · Colorectal Neoplasms (1) · Drug-Related Side Effects and Adverse Reactions (1) · Esophageal Neoplasms (1) · Heart Failure (1)
University Hospital, Caen (3) · Fudan University (2) · Groupe Hospitalier Pitie-Salpetriere (2) · H. Lee Moffitt Cancer Center and Research Institute (2) · Tianjin Medical University Cancer Institute and Hospital (2) · ARCAGY/ GINECO GROUP (1) · Affiliated Hospital of Jiangnan University (1) · Anhui Provincial Hospital (1) · BeOne Medicines (1) · Cancer Institute and Hospital, Chinese Academy of Medical Sciences (1) · Central South University (1) · Chinese University of Hong Kong (1) · Day One Biopharmaceuticals, Inc. (1) · Fuzhou General Hospital (1) · Gencurix, Inc. (1)
China (18) · France (6) · United States (6) · South Korea (3) · Australia (2) · Israel (2) · Italy (2) · Spain (2) · Austria (1) · Belgium (1) · Brazil (1) · Canada (1) · Czechia (1) · Denmark (1) · Egypt (1)
Adam Ostrowski, MD (1) · Alberto A Gabizon, MD, PhD (1) · Dingwei Ye (1) · Jeffrey Lancet, M.D. (1) · Jianmin Xu (1) · Joachim Alexandre, MD, PhD (1) · Ju-Young Shin, PhD (1) · Li Zhang, PhD (1) · Ming Cui, Doctor (1) · Moshe Gatt, MD (1) · Paul S Gaynon, MD (1) · Scott Antonia, M.D. (1) · Simon Yu (1) · Wenjie Jiao, PhD (1)
PMID 14998846, PMID 17008692, PMID 21296855, PMID 25415656, PMID 26408258, PMID 27912846, PMID 31558250, PMID 31988143, PMID 32353110, PMID 32408984, PMID 33092403, PMID 34370839, PMID 36426808, PMID 38291372, PMID 39395266, PMID 39627133, PMID 41198344, PMID 42361329
2025 (1)